NFKB1 and neoplasm: Immunohistochemical analysis of the xenograft tumors further confirmed the enhanced anti-tumor effect of the combination therapy, as evidenced by the lowest expression levels of the proliferation marker Ki67 and the pro-survival protein NF-κB in this group (Figure 5E).